Article
Pharmacology & Pharmacy
Jong-Min Kim, Jihyeon Noh, Jin-Woo Park, Hyewon Chung, Kyoung-Ah Kim, Seung Bin Park, Jun-Seok Lee, Ji-Young Park
Summary: This study aimed to compare the anticoagulant effects of DAB and its metabolite DABG in humans. The results showed that DABG exhibited weaker anticoagulant effects compared to DAB.
Review
Pediatrics
Jie Chen, Guoshan Bi, Fei Wu, Xiao Qin
Summary: This study evaluates the efficacy and safety of direct oral anticoagulants (DOACs) in pediatric venous thromboembolism (PVTE) through a meta-analysis of randomized control trials. The results suggest that DOACs can reduce the risk of recurrent VTE compared to standard anticoagulation, with similar mortality rates and lower major bleeding risk. However, there is a higher risk of clinically relevant nonmajor bleeding. Dabigatran and rivaroxaban show similar effects in PVTE treatment.
PEDIATRIC RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Samuel Z. Goldhaber, Walter Ageno, Ivan B. Casella, Kok Han Chee, Sebastian Schellong, Daniel E. Singer, Isabelle Voccia, Wenbo Tang, Sam Schulman
Summary: RE-COVERY DVT/PE is an international observational study comparing the safety and effectiveness of dabigatran and vitamin K antagonists in patients with deep vein thrombosis and/or pulmonary embolism. The study found that dabigatran had lower rates of bleeding events compared to vitamin K antagonists, but similar rates of symptomatic venous thromboembolism or related mortality. The results of this observational study with 1-year follow-up were consistent with randomized clinical trials.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2022)
Article
Medicine, General & Internal
Runze Song, Ruisheng Qu, Yu Wang, Dong Zhou, Anping Zhang
Summary: This study aims to evaluate the efficacy and safety of rivaroxaban and dabigatran etexilate in preventing venous thromboembolism after joint replacement through a randomized controlled trial. The results will provide important clinical evidence for decision-making.
Review
Oncology
Lai Heng Lee, Pongwut Danchaivijitr, Noppacharn Uaprasert, Harinder Gill, Dennis Lee Sacdalan, Gwo Fuang Ho, Rajiv Parakh, Paresh Pai, Jen-Kuang Lee, Nannette Rey, Alexander T. Cohen
Summary: Direct oral anticoagulants (DOACs) have shown comparable efficacy and safety outcomes in Asian patients with cancer-associated thrombosis (CAT) compared to other races. Apixaban, edoxaban, or rivaroxaban can be considered as reasonable alternatives to low-molecular-weight heparin (LMWH) for anticoagulation in Asian patients with CAT.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Review
Pediatrics
Julie Jaffray, Guy Young
Summary: With the increasing incidence of thromboembolism in children and improvement in management for patients with medically complex diseases, there is a need for expanded availability of safe and effective anticoagulant medications. Direct oral anticoagulants provide an alternative and potentially safer choice for children, as they are available in oral formulations and do not require drug monitoring. The approval of direct factor Xa inhibitor, rivaroxaban, and direct thrombin inhibitor, dabigatran, is changing the field of paediatric anticoagulation.
LANCET CHILD & ADOLESCENT HEALTH
(2022)
Article
Endocrinology & Metabolism
Yu-Huan Gu, Brian T. Hawkins, Yoshikane Izawa, Yoji Yoshikawa, James A. Koziol, Gregory J. del Zoppo
Summary: A study found that anti-thrombin activity decreases the risk of intracerebral hemorrhage by inhibiting thrombin-mediated degradation of cerebral microvessel basal lamina matrix. This has implications for understanding focal ischemia and other related conditions.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
(2022)
Article
Engineering, Multidisciplinary
Maha M. Abou El-Alamin, Dina A. Mohamed, Safaa S. Toubar
Summary: Selective, sensitive, and reproducible ion-selective electrodes containing dabigatran etexilate-phosphotungstate ion pair as a modifier have been fabricated to determine dabigatran etexilate in pure and pharmaceutical dosage form with high accuracy and precision.
Review
Medicine, General & Internal
Xiaole Su, Bingjuan Yan, Lihua Wang, Hong Cheng, Yipu Chen
Summary: DOACs have similar efficacy as warfarin in the treatment of acute VTE, reducing recurrent VTE and VTE-related death, but are significantly superior to warfarin in reducing the risk of bleeding. There is no significant difference in the efficacy and safety of DOACs across different CrCl stratifications, but apixaban might be associated with a lower risk of bleeding in patients with VTE and CrCl >80 mL/min.
Article
Medical Laboratory Technology
Oksana Volod, Marian Rollins-Raval, Andrew J. Goodwin, Russell A. Higgins, Thomas Long, Wayne L. Chandler, Neil S. Harris, Huy P. Pham, James Alexander Isom, Karen Moser, John D. Olson, Kristi J. Smock, Amanda VanSandt, Geoffrey Wool, Dong Chen
Summary: This study evaluated the performance of DOAC-specific assays for dabigatran and rivaroxaban, as well as the interlaboratory variability in measuring these drugs. Results showed reasonable performance of the assays, with specific variations in responsiveness of routine clotting assays to different DOACs. The undiluted thrombin time was found to be too sensitive for drug-level monitoring but suitable as a qualitative screening assay.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2022)
Review
Medicine, General & Internal
Rachel P. Rosovsky, Eva Kline-Rogers, Leslie Lake, Tracy Minichiello, Gregory Piazza, Bishoy Ragheb, Beth Waldron, Daniel M. Witt, Stephan Moll
Summary: In clinical practice, direct oral anticoagulants (DOACs) are used for venous thromboembolism treatment and prevention. The use of DOACs in obese patients is still controversial, with limited supporting data previously. There are also evidence gaps regarding the treatment of severe obesity and the appropriate use of DOACs in different situations.
AMERICAN JOURNAL OF MEDICINE
(2023)
Article
Oncology
Jingyi Gong, Zsofia D. Drobni, Raza M. Alvi, Sean P. Murphy, Ryan J. Sullivan, Sarah E. Hartmann, Hannah K. Gilman, Hang Lee, Leyre Zubiri, Vineet K. Raghu, Rebecca S. Karp-Leaf, Amna Zafar, Daniel A. Zlotoff, Matthew J. Frigault, Kerry L. Reynolds, Tomas G. Neilan
Summary: The study found that the risk of VTE was 7.4% at 6 months and 13.8% at 1 year after starting an ICI, with a significantly increased rate of VTE. Factors such as age, medical history, and underlying diseases can predict the risk of VTE in patients receiving ICIs.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Multidisciplinary Sciences
Hyun-Jung Lee, Hyung-Kwan Kim, Bong-Sung Kim, Kyung-Do Han, Jun-Bean Park, Heesun Lee, Seung-Pyo Lee, Yong-Jin Kim
Summary: In patients on oral anticoagulant and PPI co-therapy, NOACs were associated with a lower risk of upper gastrointestinal bleeding and mortality compared to warfarin, while there was no difference among the oral anticoagulants for stroke prevention.
Review
Pediatrics
Maha Al-Ghafry, Anjali Sharathkumar
Summary: Venous thromboembolism is a common complication among pediatric patients, with a 130% increase in the past decade. Direct oral anticoagulants (DOACs), a newer class of medication, provide the advantages of oral administration without dose adjustments. This article provides an overview of DOACs, focusing on their use in pediatric patients, specifically rivaroxaban and dabigatran.
FRONTIERS IN PEDIATRICS
(2022)
Article
Multidisciplinary Sciences
Tailai He, Fei Han, Jiahao Wang, Yihe Hu, Jianxi Zhu
Summary: The study results demonstrate that all anticoagulant drugs showed some effectiveness in VTE prophylaxis, with fondaparinux and rivaroxaban being safer and more effective than other drugs.
Article
Oncology
Toma S. Omofoye, Anganile Kalinga, Ramapriya Ganti, Frank J. Minja, Timothy B. Rooney
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Prarthna V. Bhardwaj, Renuka Dulala, Senthil Rajappa, Chandravathi Loke
Summary: The management of breast cancers in India needs greater emphasis on awareness, early detection, standard pathologic testing, and cost-effective solutions. With standardized management, outcomes similar to those of developed countries can be expected. Additionally, clinical trials aimed at a more diverse population in LMICs like India should be undertaken.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Victoria E. Forbes, Mary D. Chamberlin, Vincent Dusabejambo, Tim Walker, Steve P. Bensen, Norrisa Haynes, Kathryn Nunes, Veauthyelau Saint-Joy, Frederick L. Makrauer
Summary: Global health education needs to adapt to the challenges we face, such as inequities and pandemics. Virtual teaching models are effective in delivering global health education and improving outcomes through bidirectional learning and equitable partnerships.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Tefta Isufaj Haliti, Ilir Hoxha, Rubena Mojsiu, Rohini Mandal, Goksu Goc, Kreshnike Dedushi Hoti
Summary: The IOTA Simple Rules have high diagnostic performance in distinguishing between benign and malignant adnexal masses, providing a reliable tool for early diagnosis of ovarian cancer.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Cecilia Felix Penido Mendes de Sousa, Jared Pasetsky, Gustavo Nader Marta, Megan Kassick, Fabio Ynoe Moraes, Luqman K. Dad
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary D. Chamberlin, Dafina Ademi Islami, Shqiptar Demaci, Richard J. Barth Jr
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Jeta Bunjaku, Arber Lama, Tawanda Pesanayi, Jeton Shatri, Mary Chamberlin, Ilir Hoxha
Summary: The evidence suggests that lifestyle factors such as alcohol and coffee intake may increase the risk of lung cancer, while tea intake may have a protective effect. However, the quality of evidence is currently low and further research is needed.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary Chamberlin, Christopher Booth, Gabriel A. Brooks, Achille Manirakiza, Fidel Rubagumya, Verna Vanderpuye
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Anne Christine Buteau, Alicia Castelo-Loureiro, Regina Barragan-Carrillo, Suyapa Bejarano, Alba J. Kihn-Alarcon, Enrique Soto-Perez-de-Celis
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Ilir Hoxha, Fitim Sadiku, Lot Hoxha, Midhet Nasim, Marie Anne Christine Buteau, Krenare Grezda, Mary D. Chamberlin
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)